BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has announced a collaboration to manufacture BiVictriX’s antibody-drug conjugates (ADC) with Abzena Limited (Abzena), a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics.   The collaboration will allow BiVictriX to cost-effectively manufacture its anti-can...